drugset / Trial / NCT02172222

Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers

NCT02172222

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative bioavailability of BI 10773 and of linagliptin after concomitant multiple oral administration of 50 mg BI 10773 tablets and 5 mg linagliptin in comparison to 50 mg BI 10773 and 5 mg linagliptin given alone.

Timeline

Start
2009-07
Primary completion
2009-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 50 mg Oral
Subject Linagliptin Small molecule 5 mg Oral

Indications

No indication recorded.